Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBFB retroviral vector is an experimental gene therapy tool designed to restore the expression of the Core Binding Factor Beta (CBFB) subunit in hematopoietic cells. CBFB is a critical component of the Core Binding Factor (CBF) transcription complex, which also includes the DNA-binding subunit RUNX1. In the context of Acute Myeloid Leukemia (AML), reduced CBFB expression is frequently observed, leading to impaired hematopoiesis and compensatory upregulation of RUNX1. This retroviral vector is used in preclinical research to demonstrate that restoring CBFB levels can normalize RUNX1 expression and potentially reverse preleukemic phenotypes, suggesting a therapeutic strategy for AML patients with CBF pathway deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CBFB retroviral vector.